Morgan Stanley Belite Bio, Inc Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Belite Bio, Inc stock. As of the latest transaction made, Morgan Stanley holds 6,090 shares of BLTE stock, worth $277,095. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,090
Previous 22,421
72.84%
Holding current value
$277,095
Previous $1.03 Million
77.27%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding BLTE
# of Institutions
12Shares Held
58.3KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA16.7KShares$758,4850.0% of portfolio
-
Marshall Wace, LLP London, X010.6KShares$481,5720.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.7KShares$395,8500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$304,8500.0% of portfolio
-
Cubist Systematic Strategies, LLC Stamford, CT4.79KShares$217,8540.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.13B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...